Kane Biotech Inc.
KNBIF
$0.03
$0.006.40%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -99.34% | -95.54% | 646.49% | 111.53% | 4,579.10% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -99.34% | -95.54% | 646.49% | 111.53% | 4,579.10% |
| Cost of Revenue | -98.13% | -72.05% | 2,830.68% | 779.77% | 20,315.38% |
| Gross Profit | -100.90% | -112.49% | -0.34% | -347.22% | 2,241.14% |
| SG&A Expenses | -62.00% | -85.88% | 12.53% | -63.70% | 35.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -71.15% | -82.59% | 19.21% | -30.13% | 86.58% |
| Operating Income | 11.96% | 75.30% | 8.19% | 36.67% | 38.11% |
| Income Before Tax | 11.37% | 71.66% | 23.38% | 30.87% | 46.35% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 11.37% | 71.66% | 23.38% | 114.51% | 46.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -2,036.99% | 153.35% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 0.72% | -103.75% | 17.99% | 33.48% | 56.78% |
| EBIT | 11.96% | 75.30% | 8.19% | 36.67% | 38.11% |
| EBITDA | 21.83% | 78.39% | 5.24% | 38.35% | 39.04% |
| EPS Basic | 58.06% | -102.95% | 27.85% | 36.36% | 61.73% |
| Normalized Basic EPS | 63.64% | 76.19% | 33.96% | 47.17% | 52.17% |
| EPS Diluted | 81.43% | -103.67% | 27.85% | 36.36% | 14.63% |
| Normalized Diluted EPS | 63.64% | 74.29% | 33.96% | 47.17% | 52.17% |
| Average Basic Shares Outstanding | 136.15% | 23.17% | 13.81% | 4.34% | 13.26% |
| Average Diluted Shares Outstanding | 136.15% | 14.24% | 13.81% | 4.34% | 13.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |